5564. Lomustine

Nomenclature

CAS number: 13010-47-4
N-(2-Chloroethyl)-N′-cyclohexyl-N-nitrosourea; 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea; CCNU; NSC-79037; RB-1509; Cecenu (Medac); CeeNU (BMS); CiNU (BMS).
C9H16ClN3O2; mol wt 233.70.
C 46.25%, H 6.90%, Cl 15.17%, N 17.98%, O 13.69%.

Description and references

Chloroethylnitrosourea derivative with antitumor activity. Synthesis: T. P. Johnston et al., J. Med. Chem. 9, 892 (1966). Clinical review: S. K. Carter, J. W. Newman, Cancer Chemother. Rep. Part 3 1, 136 (1968). Physiological disposition: V. T. Oliverio et al., Cancer Res. 30, 1330 (1970). Toxicology and pharmacology: G. R. Thompson, R. E. Larson, Toxicol. Appl. Pharmacol. 21, 405 (1972); V. T. Oliverio, Cancer Chemother. Rep. Part 3 4, 13 (1973). Use in canine epitheliotropic lymphoma: R. E. Risbon et al., J. Vet. Intern. Med. 20, 1389 (2006). Comprehensive description: F. J. Al-Shammary, Anal. Profiles Drug Subs. 19, 315-340 (1990).

Chemical structure

Properties

Yellow powder, mp 90°. Freely sol in chloroform; sol in ethanol, acetone. Soly in water, 0.1N NaOH, 0.1N HCl or 10% ethanol: <0.05 mg/ml; in absolute ethanol: 70 mg/ml. The bulk drug should be stored in a deep freeze and protected from moisture. LD50 in male mice (mg/kg): 51 orally; 56 i.p.; 61 s.c. (Thompson, Larson).

Caution

This substance is reasonably anticipated to be a human carcinogen: Report on Carcinogens, Eleventh Edition (PB2005-104914, 2004) p III-52.

Therapeutic Category

Antineoplastic.

Therapeutic Category (Veterinary)

Antineoplastic.

Keywords

Antineoplastic; Alkylating Agents; Nitrosoureas